NAMPT
Nicotinamide phosphoribosyltransferase (NAMPT), also known as Visfatin, is a rate-limiting enzyme in the NAD+ salvage pathway, catalyzing the conversion of nicotinamide to nicotinamide mononucleotide.
Nicotinamide phosphoribosyltransferase (NAMPT), also known as Visfatin, is a rate-limiting enzyme in the NAD+ salvage pathway, catalyzing the conversion of nicotinamide to nicotinamide mononucleotide. As a critical metabolic enzyme, NAMPT plays an essential role in maintaining cellular NAD+ levels, which are required for numerous metabolic and signaling processes. In cancer, particularly triple-negative breast cancer (TNBC), NAMPT is frequently upregulated to meet the increased bioenergetic and biosynthetic demands of rapidly proliferating tumor cells. Beyond its role in malignancy, NAMPT expression is also associated with metabolic disorders including type 2 diabetes mellitus and autoimmune thyroid disease, reflecting its broader significance in systemic metabolism and immune regulation. These multiple disease associations, coupled with its metabolic essentiality in cancer cells, have positioned NAMPT as an increasingly promising therapeutic target for drug discovery.
Where the papers sit
10 papers from the last 6 months study NAMPT directly · updated from PubMed 3 Oct 2026
Study type 0 clinical trials · 1 observational · 1 human data · 7 preclinical · 1 unclassified
Themes no clear themes · 1 new direction
Those 10 do not share a common subject.
-
NAMPT-targeting cancer therapeutics appear alongside studies of cellular aging, metabolic disease, vascular deterioration and periodontitis. The cancer-focused entries investigate PROTACs, enediyne degraders and dual inhibitors involving PD-1/PD-L1, SHP2 or MLK3, including triple-negative breast cancer. The remaining studies share no biological question with this drug-discovery work. No coherent research direction can be inferred from the cluster as a whole.
NAMPT is a protective vascular-aging regulator and a proteolytic substrate, not only a suppressible cancer target
The endothelial C/EBPβ/AEP pathway study in aging mice 42748238Sep finds that AEP cleaves NAMPT, causing systemic NAD+ depletion and senescence, while an AEP-resistant NAMPT mutant ameliorates vascular aging and extends lifespan. Whereas the cancer studies treat NAMPT inhibition or degradation as the therapeutic objective, this study assigns NAMPT a protective role in maintaining vascular and organismal health; the resulting direction is to preserve NAMPT or prevent its cleavage rather than suppress it.
NAMPT (Nicotinamide Phosphoribosyltransferase)
Papers
The 10 papers from the last 6 months that study NAMPT directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (10)
- USP22 alleviates oxidative stress-induced BMSCs senescence by stabilizing SPI1 protein. Molecular genetics and genomics : MGG · 16 Sept 2026 PMID 42749843
- Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging. Science advances · 16 Sept 2026 PMID 42748238
- Enediyne Chimeras for Targeted NAMPT Degradation: Enhancing Cytotoxicity via a Radical Clock. The Journal of organic chemistry · 27 Jul 2026 PMID 42504523
- Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer. Journal of chemical information and modeling · 22 Jul 2026 PMID 42486779
- Adipocytokine Profiles in Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease: Associations With Metabolic and Hormonal Parameters. Physiological research · 15 Jul 2026 PMID 42455070
- Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming. Journal of medicinal chemistry · 6 Jul 2026 PMID 42406471
- 4-Arylindolines Bearing a Pyrido[3,2-d]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism. Journal of medicinal chemistry · 29 Jun 2026 PMID 42366729
- Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of medicinal chemistry · 22 Jun 2026 PMID 42324937
- Mixed Lineage Kinase Suppression in Triple-Negative Breast Cancer: Identification of a Dual Inhibitor Targeting MLK3 and NAMPT. Journal of medicinal chemistry · 10 Jun 2026 PMID 42269602
- Obstructive Sleep Apnea Associated with Periodontitis: Evidence from Mendelian Randomization and Salivary Proteomics. Journal of proteome research · 30 Apr 2026 PMID 42057688
By study type
Observational studies and case reports (1)
- Adipocytokine Profiles in Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease: Associations With Metabolic and Hormonal Parameters. Physiological research · 15 Jul 2026 PMID 42455070
Human data, design not indexed (1)
- Obstructive Sleep Apnea Associated with Periodontitis: Evidence from Mendelian Randomization and Salivary Proteomics. Journal of proteome research · 30 Apr 2026 PMID 42057688
Preclinical: animal, cell and lab studies (7)
- USP22 alleviates oxidative stress-induced BMSCs senescence by stabilizing SPI1 protein. Molecular genetics and genomics : MGG · 16 Sept 2026 PMID 42749843
- Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging. Science advances · 16 Sept 2026 PMID 42748238
- Enediyne Chimeras for Targeted NAMPT Degradation: Enhancing Cytotoxicity via a Radical Clock. The Journal of organic chemistry · 27 Jul 2026 PMID 42504523
- Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer. Journal of chemical information and modeling · 22 Jul 2026 PMID 42486779
- 4-Arylindolines Bearing a Pyrido[3,2-d]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism. Journal of medicinal chemistry · 29 Jun 2026 PMID 42366729
- Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of medicinal chemistry · 22 Jun 2026 PMID 42324937
- Mixed Lineage Kinase Suppression in Triple-Negative Breast Cancer: Identification of a Dual Inhibitor Targeting MLK3 and NAMPT. Journal of medicinal chemistry · 10 Jun 2026 PMID 42269602
Unclassified: not yet indexed with MeSH (1)
- Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming. Journal of medicinal chemistry · 6 Jul 2026 PMID 42406471
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-08-12. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.